Is Caribou Biosciences, Inc. (CRBU) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 15.6% / 30% | 123.2% / 30% | 1.9% / 30% | 175.13% / 5% | ✗ NOT HALAL |
| DJIM | 15.6% / 33% | 123.2% / 33% | 1.9% / 33% | 175.13% / 5% | ✗ NOT HALAL |
| MSCI | 8.5% / 33% | 66.9% / 33% | 1.0% / 33% | 175.13% / 5% | ✗ NOT HALAL |
| S&P | 15.6% / 33% | 123.2% / 33% | 1.9% / 33% | 175.13% / 5% | ✗ NOT HALAL |
| FTSE | 8.5% / 33% | 66.9% / 33% | 1.0% / 50% | 175.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -722.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -79.0% | |
| Return on Assets (ROA) | -34.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$111M |
| Free Cash Flow | -$112M |
| Total Debt | $27M |
| Debt-to-Equity | 22.3 |
| Current Ratio | 5.7 |
| Total Assets | $175M |
Price & Trading
| Last Close | $1.91 |
| 50-Day MA | $1.73 |
| 200-Day MA | $1.86 |
| Avg Volume | 1.2M |
| Beta | 2.5 |
|
52-Week Range
$0.66
| |
About Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Caribou Biosciences, Inc. (CRBU) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Caribou Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Caribou Biosciences, Inc.'s debt ratio?
Caribou Biosciences, Inc.'s debt ratio is 15.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.5%.
What are Caribou Biosciences, Inc.'s key financial metrics?
Caribou Biosciences, Inc. has a market capitalization of $172M, and revenue of $11M. Return on equity stands at -79.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.